US 12,440,535 B2
IL-4 derived peptide fragments for use in the treatment of diabetic nephropathy
Eva Steiness, Hellerup (DK)
Assigned to SERODUS APS, Copenhagen N (DK)
Appl. No. 18/724,136
Filed by SERODUS APS, Copenhagen N (DK)
PCT Filed Apr. 28, 2023, PCT No. PCT/EP2023/061314
§ 371(c)(1), (2) Date Jun. 25, 2024,
PCT Pub. No. WO2023/209186, PCT Pub. Date Nov. 2, 2023.
Claims priority of application No. 22170903 (EP), filed on Apr. 29, 2022.
Prior Publication US 2025/0064887 A1, Feb. 27, 2025
Int. Cl. A61K 38/10 (2006.01); A61P 13/12 (2006.01)
CPC A61K 38/10 (2013.01) [A61P 13/12 (2018.01)] 1 Claim
 
1. A method for the treatment of diabetic nephropathy, said method comprising administering a therapeutically effective amount of a peptide or a pharmaceutically acceptable salt thereof, wherein the peptide is a dimer comprising two fragments, each fragment consisting of the amino acid sequence AQFHRHKQLIRFLKRA (SEQ ID NO:1), wherein each fragment is covalently connected at its C-terminal through a linker, and wherein said peptide has the structure of Formula (II):

OG Complex Work Unit Chemistry